NO20065117L - Sammensetning omfattende en JNK inhibitor og syklosporin. - Google Patents

Sammensetning omfattende en JNK inhibitor og syklosporin.

Info

Publication number
NO20065117L
NO20065117L NO20065117A NO20065117A NO20065117L NO 20065117 L NO20065117 L NO 20065117L NO 20065117 A NO20065117 A NO 20065117A NO 20065117 A NO20065117 A NO 20065117A NO 20065117 L NO20065117 L NO 20065117L
Authority
NO
Norway
Prior art keywords
cyclosporin
composition
jnk inhibitor
cancer
treatment
Prior art date
Application number
NO20065117A
Other languages
English (en)
Inventor
Pierre-Alain Vitte
Christian Rommel
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20065117L publication Critical patent/NO20065117L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Den foreliggende oppfinnelsen angår en sammensetning omfattende en JNK-inhibitor og et syklosporin, særhg for behandling av nevronale lidelser, autoimmune sykdommer, kreft og kardiovaskulære sykdommer.
NO20065117A 2004-04-08 2006-11-07 Sammensetning omfattende en JNK inhibitor og syklosporin. NO20065117L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04101468 2004-04-08
PCT/EP2005/051572 WO2005097116A1 (en) 2004-04-08 2005-04-08 Composition comprising a jnk inhibitor and cyclosporin

Publications (1)

Publication Number Publication Date
NO20065117L true NO20065117L (no) 2006-11-07

Family

ID=34928946

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065117A NO20065117L (no) 2004-04-08 2006-11-07 Sammensetning omfattende en JNK inhibitor og syklosporin.

Country Status (13)

Country Link
US (1) US20080039377A1 (no)
EP (1) EP1850846A1 (no)
JP (2) JP5080241B2 (no)
KR (2) KR20060134198A (no)
CN (1) CN1960726A (no)
AU (2) AU2005230416B2 (no)
BR (1) BRPI0509755A (no)
CA (1) CA2561907A1 (no)
EA (1) EA017893B1 (no)
IL (1) IL178417A0 (no)
NO (1) NO20065117L (no)
UA (1) UA91676C2 (no)
WO (1) WO2005097116A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
EP2026802A2 (en) * 2006-06-02 2009-02-25 Laboratoires Serono SA Jnk inhibitors for treatment of skin diseases
EP2137173A2 (en) * 2007-04-17 2009-12-30 Laboratoires Serono SA Process for the preparation of piperazine benzothiazoles
AU2008304313B2 (en) 2007-09-26 2013-01-10 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US8828924B2 (en) * 2009-05-14 2014-09-09 University Of Maryland, Baltimore Methods of treating a diabetic embryopathy
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
EP3679933A1 (en) 2011-04-29 2020-07-15 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
US20140163075A1 (en) * 2011-06-01 2014-06-12 Netherland Cancer Institute Modulation of the ubiquitin-proteasome system (ups)
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
CN104903331A (zh) * 2013-01-24 2015-09-09 山东亨利医药科技有限责任公司 Jnk抑制剂
KR20220025911A (ko) 2013-05-03 2022-03-03 셀렉타 바이오사이언시즈, 인크. Cd4+ 조절 t 세포를 증진시키기 위한 방법 및 조성물
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
KR20170045344A (ko) 2014-09-07 2017-04-26 셀렉타 바이오사이언시즈, 인크. 항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물
MX2019010757A (es) 2017-03-11 2020-01-20 Selecta Biosciences Inc Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
KR20230164862A (ko) * 2022-05-26 2023-12-05 연세대학교 산학협력단 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
ES2059558T3 (es) * 1987-06-17 1994-11-16 Sandoz Ag Ciclosporins y su uso como productos farmaceuticos.
US6514745B1 (en) * 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
EP1193267A1 (en) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein JunKinases

Also Published As

Publication number Publication date
EA200601841A1 (ru) 2007-04-27
EA017893B1 (ru) 2013-04-30
AU2010212339B2 (en) 2012-07-19
JP5080241B2 (ja) 2012-11-21
EP1850846A1 (en) 2007-11-07
CN1960726A (zh) 2007-05-09
JP2012136550A (ja) 2012-07-19
IL178417A0 (en) 2007-02-11
BRPI0509755A (pt) 2007-10-16
KR20060134198A (ko) 2006-12-27
UA91676C2 (ru) 2010-08-25
WO2005097116A1 (en) 2005-10-20
JP2007532517A (ja) 2007-11-15
AU2005230416A1 (en) 2005-10-20
KR20120135441A (ko) 2012-12-13
AU2005230416B2 (en) 2010-05-13
US20080039377A1 (en) 2008-02-14
CA2561907A1 (en) 2005-10-20
AU2010212339A1 (en) 2010-09-09

Similar Documents

Publication Publication Date Title
NO20065117L (no) Sammensetning omfattende en JNK inhibitor og syklosporin.
BRPI0410905A (pt) inibidores de p-38
EA200870019A1 (ru) Лактамовые соединения и способы их применения
DK1809280T3 (da) Mitotiske kinesininhibitorer og fremgangsmåder til anvendelse deraf
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NO20065368L (no) Terapeutiske blandinger inneholdende minst et pyrrolobenzodiazepinderivat og fludarabin
ECSP045429A (es) Combinacion de compuestos organicos
NO20034056D0 (no) Proliferative sykdommer
EA200700225A1 (ru) Аналоги тетрапептида
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
ZA200701661B (en) Isoindoline compounds and methods of making and using the same
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
DK2201840T3 (da) Hæmmere af Brutons tyrosinkinase
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
NO20062694L (no) Inhibitor av mutant form av KIT
NO20065762L (no) Prodroger av pyrrolypyrimidin-ERK-proteinkinaseinhibitorer.
EA200802324A1 (ru) Новая форма введения рацекадотрила
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
NO20064896L (no) Fremgangsmater for behandling av autoimmune og inflammatoriske sykdommer
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
DE60329326D1 (de) Tace inhibitoren
MXPA05003718A (es) Compuestos x-nitro, sus composiciones farmaceuticas y sus usos.

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application